Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.

Čájet eará veršuvnnaid (1)

BACKGROUND: Immunomodulatory drugs have been shown to be only modestly effective in clinically definite relapsing remitting multiple sclerosis (RRMS). It has been hypothesized that their efficacy could be higher if used at the first appearance of symptoms, that is in the clinically isolated syndrom...

Bibliográfalaš dieđut
Váldodahkkit:	Clerico, M, Faggiano, F, Palace, J, Rice, G, Tintorè, M, Durelli, L
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2008

Geahča maid

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Dahkki: Clerico, M, et al.
Almmustuhtton: (2008)

Treatment for delaying conversion of the first demyelinating event to multiple sclerosis: a Cochrane review on use of recombinant interferon beta or glatiramer acetate
Dahkki: Clerico, M, et al.
Almmustuhtton: (2005)

Recombinant interferon-beta efficacy in preventing conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane meta-analysis
Dahkki: Clerico, M, et al.
Almmustuhtton: (2006)

Early treatment to prevent conversion of clinically isolated syndrome to clinically defined multiple sclerosis: a Cochrane metanalysis
Dahkki: Clerico, M, et al.
Almmustuhtton: (2008)

Conversion from clinically isolated syndromes to multiple sclerosis: how could we prevent it? A Cochrane review of published trials
Dahkki: Clerico, M, et al.
Almmustuhtton: (2007)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
Dahkki: Valéria Coelho Santa Rita Pereira, et al.
Almmustuhtton: (2012-10-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
Dahkki: Clerico, M, et al.
Almmustuhtton: (2007)

Prevention of conversion of clinically isolated syndromes to clinically defined multiple sclerosis. Evidence from a Cochrane meta-analysis
Dahkki: Clerico, M, et al.
Almmustuhtton: (2008)

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation
Dahkki: GJ Melendez-Torres, et al.
Almmustuhtton: (2017-09-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
Dahkki: E.J. Ramos González, et al.
Almmustuhtton: (2021-05-01)

To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
Dahkki: Clerico, M, et al.
Almmustuhtton: (2009)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
Dahkki: Clerico, M, et al.
Almmustuhtton: (2006)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
Dahkki: N. Y. Lasch
Almmustuhtton: (2015-12-01)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
Dahkki: Katarzyna Kapica-Topczewska, et al.
Almmustuhtton: (2019-01-01)

Pharmacoeconomic assessment of the effectiveness of glatiramer acetate (Copaxone®) in patients with multiple sclerosis
Dahkki: G. Ya. Shvarts
Almmustuhtton: (2005-06-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Dahkki: Özlem Taşkapılıoğlu, et al.
Almmustuhtton: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Dahkki: Özlem Taşkapılıoğlu, et al.
Almmustuhtton: (2012-03-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
Dahkki: Oscar Fernández
Almmustuhtton: (2012-08-01)

Treatment Challenges in Multiple Sclerosis – A Continued Role for Glatiramer Acetate?
Dahkki: Massimiliano Mirabella, et al.
Almmustuhtton: (2022-04-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
Dahkki: Mikhail Melnikov, et al.
Almmustuhtton: (2020-01-01)

Nicolau syndrome following glatiramer acetate for multiple sclerosis: Case and review of reports
Dahkki: Methma Udawatta, et al.
Almmustuhtton: (2024-04-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
Dahkki: Aaron Boster, et al.
Almmustuhtton: (2011-09-01)

Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-β and glatiramer acetate for multiple sclerosis
Dahkki: P Tappenden, et al.
Almmustuhtton: (2004-06-01)

Can Glatiramer Acetate Prevent Cognitive Impairment by Modulating Oxidative Stress in Patients with Multiple Sclerosis?
Dahkki: Anna Gil-Sánchez, et al.
Almmustuhtton: (2024-04-01)

Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon β-1b on Experimental Autoimmune Encephalomyelitis
Dahkki: Genaro Gabriel Ortíz, et al.
Almmustuhtton: (2022-06-01)

Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation
Dahkki: Arielle Kasindi, et al.
Almmustuhtton: (2022-05-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
Dahkki: Arthur Komlosh, et al.
Almmustuhtton: (2019-07-01)

Interleukins (IL-23 and IL-27) serum levels: Relationships with gene polymorphisms and disease patterns in multiple sclerosis patients under treatment with interferon and glatiramer acetate
Dahkki: Ioana S. Barac, et al.
Almmustuhtton: (2023-06-01)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
Dahkki: T. E. Shmidt
Almmustuhtton: (2016-12-01)

MicroRNAs Associated with Disability Progression and Clinical Activity in Multiple Sclerosis Patients Treated with Glatiramer Acetate
Dahkki: Ignacio Casanova, et al.
Almmustuhtton: (2023-10-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
Dahkki: Justin M. Honce, et al.
Almmustuhtton: (2020-09-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
Dahkki: Lyubomira Vlahova, et al.
Almmustuhtton: (2021-02-01)

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers
Dahkki: Oliver Neuhaus, et al.
Almmustuhtton: (2021-03-01)

microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Dahkki: María I. Dominguez-Mozo, et al.
Almmustuhtton: (2022-06-01)

Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis
Dahkki: Ümmügülsüm Koc, et al.
Almmustuhtton: (2023-02-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
Dahkki: Fadi Towfic, et al.
Almmustuhtton: (2014-01-01)

TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab
Dahkki: Oreja-Guevara Celia, et al.
Almmustuhtton: (2012-09-01)

Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
Dahkki: Apfel Rainer, et al.
Almmustuhtton: (2008-09-01)

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study
Dahkki: Giannini Marta, et al.
Almmustuhtton: (2012-10-01)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
Dahkki: Javier Almeida, et al.
Almmustuhtton: (2017-11-01)